We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) has launched a phase 2 trial in the UK of its investigational rheumatoid arthritis treatment otilimab for hospitalized COVID-19 patients. Read More
Interim results from a phase 1 trial showed that INO-4800 was safe and well-tolerated and induced immune responses in a majority of participants. Read More
The FDA has placed a partial clinical hold on Inovio Pharmaceuticals’ planned phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, calling for more information. Read More
Early trial data from Johnson & Johnson’s COVID-19 vaccine candidate AD26.COV2.S has shown that a single dose was enough to generate a strong antibody response. Read More
The UK is launching the first COVID-19 challenge trials, in which healthy volunteers will be exposed to the virus to assess the safety and effectiveness of vaccine candidates, the government says. Read More
Novavax yesterday launched a phase 3 clinical trial of its COVID-19 vaccine in the UK, becoming the latest drugmaker to bring a vaccine candidate to late-stage testing. Read More
The company said it will conduct a detailed analysis of the data and will plan to file for approval of Avigan in Japan for this indication as soon as next month. Read More
J&J is collaborating with HHS’ Biomedical Advanced Research and Development Authority and the National Institute for Allergy and Infectious Diseases. Read More
Johnson and Johnson (J&J) yesterday became the fourth drugmaker to begin a large-scale phase 3 trial of a COVID-19 vaccine candidate — and it will be the largest late-stage trial of a COVID-19 vaccine to date. Read More